Clinical Trial Results:
            A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Escalation and Dose-Confirmation Study to Evaluate the Safety and Efficacy of Rivaroxaban in Combination with Aspirin Alone or with Aspirin and a Thienopyridine in Subjects with Acute Coronary Syndromes  (39039039ACS2001)
The ATLAS ACS TIMI 46 Trial (Anti-Xa Therapy to Lower cardiovascular events in addition to Aspirin with or without thienopyridine therapy in Subjects with Acute Coronary Syndrome)
    
|     Summary | |
|     EudraCT number | 2006-004449-40 | 
|     Trial protocol | DE FR HU BE NL DK CZ SE SK GB BG FI IT ES | 
|     Global completion date | 
                                    22 Oct 2008
                             | 
|     Paediatric regulatory details | |
|     Is the trial part of an agreed EMA paediatric investigation plan? | 
                                        No
                                 | 
|     Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? | 
                                        No
                                 | 
|     Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? | 
                                        No
                                 | 
|     Results information | |
|     Results version number | v1(current) | 
|     This version publication date | 
                                    11 Jun 2016
                             | 
|     First version publication date | 
                                    11 Jun 2016
                             | 
|     Other versions | |
|     Summary report(s) | 39039039ACS2001 (2006-004449-40)_Ct.gov Results | 
            Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to            Commission Guideline 2012/C 302/03
            for further information.    
 
				
